GB9200420D0
(en)
|
1992-01-09 |
1992-02-26 |
James Black Foundation The Lim |
Amino acid derivatives
|
AU3509793A
(en)
|
1992-02-20 |
1993-09-13 |
James Black Foundation Limited |
Bicyclo(2.2.2.)octane derivatives as cholestocystokinin inhibitors
|
NZ265271A
(en)
|
1993-04-15 |
1997-06-24 |
Glaxo Wellcome Inc |
1-aminocarbonylmethyl-3-aminocarbonylamino-2,4-dioxo-1, 5-benzodiazepin derivatives pharmaceutical compositions thereof
|
US6334997B1
(en)
|
1994-03-25 |
2002-01-01 |
Isotechnika, Inc. |
Method of using deuterated calcium channel blockers
|
WO1995026325A2
(en)
|
1994-03-25 |
1995-10-05 |
Isotechnika Inc. |
Enhancement of the efficacy of drugs by deuteration
|
SK281433B6
(sk)
|
1994-04-14 |
2001-03-12 |
Glaxo Wellcome Inc. |
5-heterocyklo-1,5-benzodiazepínové deriváty, spôsob ich výroby, farmaceutický prostriedok s ich obsahom a ich použitie
|
EP0755394A1
(en)
|
1994-04-15 |
1997-01-29 |
Glaxo Wellcome Inc. |
A method of inducing cholecystokinin agonist activity using 1,4-benzodiazepine compounds
|
PE27497A1
(es)
|
1994-04-15 |
1997-08-07 |
Glaxo Inc |
Derivados de 1,5 benzodiazepina
|
FR2723739B1
(fr)
|
1994-08-19 |
1997-02-14 |
Sanofi Sa |
Derives de glycinamide, procedes pour leur preparation et medicaments les contenant.
|
GB9420763D0
(en)
|
1994-10-14 |
1994-11-30 |
Glaxo Inc |
Acetamide derivatives
|
GB9420747D0
(en)
|
1994-10-14 |
1994-11-30 |
Glaxo Inc |
1,5 benzodiazepine derivatives
|
US5990077A
(en)
|
1995-04-14 |
1999-11-23 |
1149336 Ontario Inc. |
Glucagon-like peptide-2 and its therapeutic use
|
AU733857B2
(en)
|
1996-04-12 |
2001-05-31 |
1149336 Ontario Inc. |
Glucagon-like peptide-2 analogs
|
FR2763337B1
(fr)
|
1997-05-13 |
1999-08-20 |
Sanofi Sa |
Nouveaux derives du triazole, un procede pour leur preparation et compositions pharmaceutiques les contenant
|
CO4970713A1
(es)
|
1997-09-19 |
2000-11-07 |
Sanofi Synthelabo |
Derivados de carboxamidotiazoles, su preparacion, composiciones farmaceuticas que los contienen
|
AR022044A1
(es)
|
1999-05-06 |
2002-09-04 |
Glaxo Group Ltd |
Derivados de 1,5-benzodiazepina
|
BR0114888A
(pt)
|
2000-10-26 |
2003-12-09 |
Sanofi Synthelabo |
Derivados de triazol e composições farmacêuticas compreendendo os mesmos
|
HUP0004741A2
(hu)
|
2000-11-28 |
2002-12-28 |
Sanofi-Synthelabo |
Kémiai eljárás tiazolszármazékok előállítására és új intermedier
|
US7112567B2
(en)
|
2001-02-16 |
2006-09-26 |
Conjuchem Inc. |
Long lasting glucagon-like peptide 2 (glp-2) for the treatment of gastrointestinal diseases and disorders
|
EP1369698A1
(en)
|
2002-06-07 |
2003-12-10 |
Bayer Ag |
Diagnostics and therapeutics for diseases associated with somatostatin receptor 5 (SSTR5)
|
EP1558607B1
(en)
*
|
2002-10-30 |
2010-05-05 |
Vertex Pharmaceuticals Incorporated |
Compositions useful as inhibitors of rock and other protein kinases
|
WO2005035793A2
(en)
|
2003-10-09 |
2005-04-21 |
Decode Genetics Ehf. |
Cckar markers and haplotypes associated with extreme weight conditions
|
WO2005051890A1
(en)
|
2003-11-19 |
2005-06-09 |
Smithkline Beecham Corporation |
Aminophenylcyclopropyl carboxylic acids and derivatives as agonists to gpr40
|
US7517910B2
(en)
|
2004-03-30 |
2009-04-14 |
Takeda Pharmaceutical Company Limited |
Alkoxyphenylpropanoic acid derivatives
|
BRPI0510273A
(pt)
|
2004-05-25 |
2007-10-30 |
Pfizer Prod Inc |
derivados de tetraazabenzo[e]azuleno e análogos destes
|
JP2007284350A
(ja)
|
2004-07-27 |
2007-11-01 |
Takeda Chem Ind Ltd |
糖尿病治療剤
|
JP2008528590A
(ja)
|
2005-01-28 |
2008-07-31 |
メルク エンド カムパニー インコーポレーテッド |
抗糖尿病性二環式化合物
|
US7759493B2
(en)
|
2005-01-31 |
2010-07-20 |
Merck Sharp & Dohme Corp. |
Antidiabetic bicyclic compounds
|
US20060177438A1
(en)
|
2005-02-08 |
2006-08-10 |
New England Medical Center |
Methods of altering absorption of hydrophobic compounds
|
UA95235C2
(en)
|
2005-05-04 |
2011-07-25 |
Зииланд Фарма А/С |
Glucagon-like-peptide-2 (glp-2) analogues
|
KR100962732B1
(ko)
|
2005-06-02 |
2010-06-09 |
에프. 호프만-라 로슈 아게 |
피페리딘-4-일-아마이드 유도체 및 sst 수용체 아형 5길항제로서 그의 용도
|
CA2627444A1
(en)
|
2005-10-24 |
2007-06-14 |
Centocor, Inc. |
Glp-2 mimetibodies, polypeptides, compositions, methods and uses
|
WO2007088857A1
(ja)
|
2006-01-31 |
2007-08-09 |
Takeda Pharmaceutical Company Limited |
遺伝子改変動物およびその用途
|
ATE479435T1
(de)
|
2006-04-14 |
2010-09-15 |
Merck Sharp & Dohme |
Substituierte imidazol-4-carboxamide als cholecystokinin-1-rezeptor-modulatoren
|
RU2008144962A
(ru)
|
2006-04-14 |
2010-05-20 |
Мерк энд Ко., Инк. (US) |
Замещенные имидазол-4-карбоксамиды в качестве модуляторов рецепторов холецистокина-1
|
TW200815377A
(en)
|
2006-04-24 |
2008-04-01 |
Astellas Pharma Inc |
Oxadiazolidinedione compound
|
EP2021327B1
(en)
|
2006-05-15 |
2012-04-04 |
Merck Sharp & Dohme Corp. |
Antidiabetic bicyclic compounds
|
WO2008028117A2
(en)
|
2006-08-31 |
2008-03-06 |
Centocor, Inc. |
Glp-2 mimetibodies, polypeptides, compositions, methods and uses
|
US8338394B2
(en)
|
2006-10-12 |
2012-12-25 |
Case Western Reserve University |
Methods for treating metabolic diseases
|
WO2008054674A2
(en)
|
2006-10-31 |
2008-05-08 |
Merck & Co., Inc. |
Antidiabetic bicyclic compounds
|
CA2667249A1
(en)
|
2006-10-31 |
2008-05-08 |
Merck & Co., Inc. |
Antidiabetic bicyclic compounds
|
CN101573376B
(zh)
|
2006-11-08 |
2013-11-06 |
西兰制药公司 |
选择性胰高血糖素样肽-2(glp-2)类似物
|
US7750048B2
(en)
|
2006-11-15 |
2010-07-06 |
Janssen Pharmaceutica Nv |
GPR40 agonists
|
WO2008067222A1
(en)
|
2006-11-28 |
2008-06-05 |
Kalypsys, Inc. |
Heterocyclic modulators of tgr5
|
US20090035306A1
(en)
|
2006-11-29 |
2009-02-05 |
Kalypsys, Inc. |
Quinazolinone modulators of tgr5
|
ES2438271T3
(es)
|
2007-01-19 |
2014-01-16 |
Intercept Pharmaceuticals, Inc. |
Ácidos biliares 23-sustituidos como moduladores de TGR5 y métodos de uso de los mismos
|
CA2676222A1
(en)
|
2007-01-26 |
2008-07-31 |
Merck & Co., Inc. |
Substituted aminopyrimidines as cholecystokinin-1 receptor modulators
|
US20080221161A1
(en)
|
2007-02-09 |
2008-09-11 |
Kalypsys, Inc. |
Heterocyclic modulators of tgr5 for treatment of disease
|
WO2009026241A1
(en)
|
2007-08-23 |
2009-02-26 |
Kalypsys, Inc. |
Heterocyclic modulators of tgr5
|
JP2010539152A
(ja)
|
2007-09-10 |
2010-12-16 |
プロシディオン・リミテッド |
代謝障害の治療のための化合物
|
AU2008302570B2
(en)
|
2007-09-20 |
2012-05-31 |
Irm Llc |
Compounds and compositions as modulators of GPR119 activity
|
KR20100075444A
(ko)
|
2007-09-21 |
2010-07-02 |
사노피-아벤티스 |
(사이클로프로필-페닐)-페닐-옥살아미드, 이의 제조 방법 및 의약으로서의 이의 용도
|
JP5427784B2
(ja)
|
2007-09-21 |
2014-02-26 |
サノフイ |
(カルボキシルアルキレン−フェニル)−フェニル−オキサルアミド、その製造方法、及び薬剤としてのその使用
|
US8354273B2
(en)
|
2007-10-17 |
2013-01-15 |
Universidad De Cordoba |
Isoforms of human somatostatin receptor type 5
|
JP2011016722A
(ja)
|
2007-10-23 |
2011-01-27 |
Astellas Pharma Inc |
チアゾリジンジオン化合物
|
TW200932219A
(en)
|
2007-10-24 |
2009-08-01 |
Astellas Pharma Inc |
Oxadiazolidinedione compound
|
SI2206707T1
(sl)
|
2007-10-24 |
2014-11-28 |
Astellas Pharma Inc. |
Azolkarboksamidna spojina ali njena sol
|
PT2202216E
(pt)
|
2007-10-26 |
2012-07-19 |
Japan Tobacco Inc |
Composto espiro em anel e sua utilização para objectivos médicos
|
AU2008319418B2
(en)
|
2007-10-29 |
2013-08-15 |
Merck Sharp & Dohme Corp. |
Antidiabetic tricyclic compounds
|
WO2009106565A1
(en)
*
|
2008-02-27 |
2009-09-03 |
Biovitrum Ab (Publ) |
Agonists of gpr119
|
JP5665160B2
(ja)
|
2008-03-26 |
2015-02-04 |
パナソニックIpマネジメント株式会社 |
発光装置および照明器具
|
EP2271619A1
(en)
|
2008-04-07 |
2011-01-12 |
Irm Llc |
Compounds and compositions as modulators of gpr119 activity
|
GB0812648D0
(en)
*
|
2008-07-10 |
2008-08-20 |
Prosidion Ltd |
Compounds
|
WO2010014739A2
(en)
|
2008-07-29 |
2010-02-04 |
Kalypsys, Inc. |
Heterocyclic modulators of tgr5
|
CN105037476B
(zh)
|
2008-07-30 |
2018-06-12 |
英特塞普特医药品公司 |
Tgr5调节剂及其使用方法
|
WO2010016846A1
(en)
|
2008-08-08 |
2010-02-11 |
Kalypsys, Inc. |
Heterocyclic modulators of tgr5 for treatment of disease
|
US20110171164A1
(en)
|
2008-09-19 |
2011-07-14 |
Nektar Therapeutics |
Polymer conjugates of glp-2-like peptides
|
WO2010056717A1
(en)
|
2008-11-17 |
2010-05-20 |
Merck Sharp & Dohme Corp. |
Substituted bicyclic amines for the treatment of diabetes
|
CN106380502A
(zh)
|
2008-11-19 |
2017-02-08 |
英特塞普特医药品公司 |
G蛋白偶联受体5(tgr5)调节剂及其使用方法
|
DK2698375T3
(en)
|
2008-11-19 |
2018-05-28 |
Intercept Pharmaceuticals Inc |
TGR5 modulators and methods for using them
|
WO2010067233A1
(en)
|
2008-12-08 |
2010-06-17 |
Pfizer Inc. |
1,2,4 triazolo [4, 3 -a] [1,5] benzodiazepin-5 (6h) -ones as agonists of the cholecystokinin-1 receptor (cck-ir)
|
WO2010085525A1
(en)
|
2009-01-23 |
2010-07-29 |
Schering Corporation |
Bridged and fused heterocyclic antidiabetic compounds
|
EP2389369A1
(en)
|
2009-01-23 |
2011-11-30 |
Schering Corporation |
Pentafluorosulpholane-containing antidiabetic compounds
|
EP2389368B1
(en)
|
2009-01-23 |
2015-06-17 |
Merck Sharp & Dohme Corp. |
Bridged and fused antidiabetic compounds
|
EP2393810A1
(en)
|
2009-02-05 |
2011-12-14 |
Schering Corporation |
Phthalazine-containing antidiabetic compounds
|
WO2010093845A1
(en)
|
2009-02-12 |
2010-08-19 |
Exelixis, Inc. |
Triazole and imidazole derivatives for use as tgr5 agonists in the treatment of diabetes and obesity
|
WO2010095663A1
(ja)
|
2009-02-18 |
2010-08-26 |
武田薬品工業株式会社 |
縮合複素環化合物
|
AU2010240142A1
(en)
|
2009-04-22 |
2011-11-10 |
Astellas Pharma Inc. |
Carboxylic acid compound
|
JP2012136438A
(ja)
|
2009-04-22 |
2012-07-19 |
Astellas Pharma Inc |
テトラゾール化合物
|
US20120172351A1
(en)
|
2009-06-09 |
2012-07-05 |
Nobuyuki Negoro |
Novel fused cyclic compound and use thereof
|
AR078522A1
(es)
|
2009-10-15 |
2011-11-16 |
Lilly Co Eli |
Compuesto de espiropiperidina, composicion farmaceutica que lo comprende, su uso para preparar un medicamento util para tratar diabetes y compuesto intermediario para su sintesis
|
EP2314616A1
(en)
|
2009-10-23 |
2011-04-27 |
Ferring B.V. |
Peptidic GLP-2 agonists
|
CA2779398A1
(en)
|
2009-10-30 |
2011-05-05 |
Mochida Phamaceutical Co., Ltd. |
Novel 3-hydroxy-5-arylisoxazole derivative
|
AR078948A1
(es)
|
2009-11-30 |
2011-12-14 |
Lilly Co Eli |
Compuestos de espiropiperidina, composicion farmaceutica que lo comprenden y su uso para preparar un medicamento util para tratar la diabetes
|
US8846739B2
(en)
|
2009-12-11 |
2014-09-30 |
Exelixis Patent Company Llc |
TGR5 agonists
|
KR20130004262A
(ko)
|
2009-12-25 |
2013-01-09 |
모찌다 세이야쿠 가부시끼가이샤 |
신규 3-히드록시-5-아릴이소티아졸 유도체
|
EP2571356A4
(en)
|
2010-05-18 |
2013-11-20 |
Merck Sharp & Dohme |
SPIROISOXAZOLIN COMPOUNDS AS SSTR5 ANTAGONISTS
|
US8530413B2
(en)
|
2010-06-21 |
2013-09-10 |
Sanofi |
Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
|
TW201215387A
(en)
|
2010-07-05 |
2012-04-16 |
Sanofi Aventis |
Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
|
TW201215388A
(en)
|
2010-07-05 |
2012-04-16 |
Sanofi Sa |
(2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
|
TW201221505A
(en)
|
2010-07-05 |
2012-06-01 |
Sanofi Sa |
Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
|
MX2013000803A
(es)
|
2010-07-23 |
2013-10-28 |
Conexios Life Sciences Pvt Ltd |
Agonistas del gpr40.
|
US8742110B2
(en)
|
2010-08-18 |
2014-06-03 |
Merck Sharp & Dohme Corp. |
Spiroxazolidinone compounds
|
CA2846680C
(en)
|
2010-08-30 |
2019-06-25 |
Takeda Gmbh |
Solid phase synthesis of h[gly2]glp-2
|
AU2011313191A1
(en)
|
2010-10-08 |
2013-05-02 |
Mochida Pharmaceutical Co., Ltd. |
Cyclic amide derivative
|
JPWO2012070554A1
(ja)
|
2010-11-22 |
2014-05-19 |
国立大学法人京都大学 |
ペプチド
|
EP2646425B1
(en)
|
2010-12-01 |
2015-06-10 |
Boehringer Ingelheim International Gmbh |
Indanyloxydihydrobenzofuranylacetic acids useful for the treatment of metabolic syndrome
|
WO2012082947A1
(en)
|
2010-12-16 |
2012-06-21 |
Irm Llc |
Compounds and compositions as tgr5 agonists
|
SG192645A1
(en)
|
2011-02-17 |
2013-09-30 |
Takeda Pharmaceutical |
Production method of optically active dihydrobenzofuran derivative
|
AU2012240122B2
(en)
*
|
2011-04-08 |
2016-08-25 |
Merck Sharp & Dohme Corp. |
Substituted cyclopropyl compounds, compositions containing such compounds and methods of treatment
|
US10752664B2
(en)
|
2011-04-08 |
2020-08-25 |
Amgen Inc. |
Method of treating or ameliorating metabolic disorders using growth differentiation factor 15 (GDF-15)
|
NZ617409A
(en)
|
2011-04-27 |
2015-08-28 |
Mochida Pharm Co Ltd |
Novel 3-hydroxyisothiazole 1-oxide derivative
|
WO2012149236A1
(en)
|
2011-04-28 |
2012-11-01 |
Bristol-Myers Squibb Company |
Novel bicyclic nitrogen containing heteroaryl tgr5 receptor modulators
|
US9006228B2
(en)
*
|
2011-06-16 |
2015-04-14 |
Merck Sharp & Dohme Corp. |
Substituted cyclopropyl compounds, compositions containing such compounds, and methods of treatment
|
WO2013054338A1
(en)
|
2011-07-06 |
2013-04-18 |
Cadila Healthcare Limited |
2-thio-imidazole derivatives as tgr5 modulators
|
AR087451A1
(es)
|
2011-08-17 |
2014-03-26 |
Lilly Co Eli |
Derivado de 1,2,3,4-tetrahidroquinolina util para tratamiento de diabetes
|
EP3431098A1
(en)
|
2011-09-12 |
2019-01-23 |
Amunix Operating Inc. |
Glucagon-like peptide-2 compositions and methods of making and using same
|
WO2013057743A1
(en)
|
2011-10-21 |
2013-04-25 |
Connexios Life Sciences Pvt. Ltd |
Process for the preparation of an aryl oxime and salts thereof
|
EP2780337B1
(en)
*
|
2011-11-15 |
2017-12-20 |
Merck Sharp & Dohme Corp. |
Substituted cyclopropyl compounds useful as gpr119 agonists
|
EP2794576A1
(en)
|
2011-12-21 |
2014-10-29 |
Ardelyx, Inc. |
Non-systemic tgr5 agonists
|
BR112014016648B1
(pt)
|
2012-01-12 |
2020-10-27 |
Shanghai Hengrui Pharmaceutical Co., Ltd. |
derivados policíclicos, seus usos e seu processo de preparação, e composição farmacêutica
|
GB2498976A
(en)
*
|
2012-02-01 |
2013-08-07 |
Prosidion Ltd |
GPR119 agonists useful in the treatment of type II diabetes
|
EP2816023A4
(en)
|
2012-02-13 |
2015-09-09 |
Takeda Pharmaceutical |
AROMATIC CORE COMPOUND
|
JP6121339B2
(ja)
|
2012-02-13 |
2017-04-26 |
武田薬品工業株式会社 |
芳香環化合物
|
TW201341356A
(zh)
|
2012-02-28 |
2013-10-16 |
皮拉馬爾企業有限公司 |
作為gpr促效劑之苯基烷酸衍生物
|
US8642585B2
(en)
|
2012-03-26 |
2014-02-04 |
Boehringer Ingelheim International Gmbh |
Indanyloxydihydrobenzofuranylacetic acids
|
WO2013154163A1
(ja)
|
2012-04-11 |
2013-10-17 |
持田製薬株式会社 |
新規5-アリール-1,2-チアジナン誘導体
|
US8809376B2
(en)
|
2012-04-30 |
2014-08-19 |
Boehringer Ingelheim International Gmbh |
Indanyloxydihydrobenzofuranylacetic acids
|
CA2872315A1
(en)
|
2012-05-03 |
2013-11-07 |
Zealand Pharma A/S |
Glucagon-like-peptide-2 (glp-2) analogues
|
US8633182B2
(en)
|
2012-05-30 |
2014-01-21 |
Boehringer Ingelheim International Gmbh |
Indanyloxyphenylcyclopropanecarboxylic acids
|
WO2014019186A1
(en)
|
2012-08-02 |
2014-02-06 |
Merck Sharp & Dohme Corp. |
Antidiabetic tricyclic compounds
|
EP2900242A4
(en)
*
|
2012-09-26 |
2016-06-29 |
Merck Sharp & Dohme |
SUBSTITUTED CYCLOPROPYL COMPOUNDS
|
KR102068381B1
(ko)
|
2012-10-26 |
2020-01-20 |
인터셉트 파마슈티컬즈, 인크. |
담즙산 유도체의 제조 방법
|
TWI692469B
(zh)
|
2012-11-09 |
2020-05-01 |
南韓商Lg化學股份有限公司 |
Gpr40受體促效劑,製造該促效劑的方法以及含有該促效劑作爲活性劑的醫藥組成物
|
CA2891348C
(en)
|
2012-11-28 |
2020-04-28 |
Intercept Pharmaceuticals, Inc. |
Treatment of pulmonary disease
|
SG11201503800QA
(en)
|
2012-11-28 |
2015-06-29 |
Boehringer Ingelheim Int |
New indanyloxydihydrobenzofuranylacetic acids
|
US20140163025A1
(en)
|
2012-12-07 |
2014-06-12 |
Boehringer Ingelheim International Gmbh |
Indanyloxydihydrobenzofuranylacetic acids
|
WO2014100025A1
(en)
|
2012-12-17 |
2014-06-26 |
Exelixis, Inc. |
Tgr5 agonists having an imidazole or triazole core with subtituent having a quaternary nitrogen
|
WO2014100021A1
(en)
|
2012-12-17 |
2014-06-26 |
Exelixis, Inc. |
Tgr5 agonists: imidazole and triazole compounds containing a quaternary nitrogen
|
WO2014096440A2
(en)
|
2012-12-21 |
2014-06-26 |
Novozymes Biopharma Dk A/S |
Composition
|
WO2014122067A1
(en)
|
2013-02-06 |
2014-08-14 |
Boehringer Ingelheim International Gmbh |
New indanyloxydihydrobenzofuranylacetic acids
|
EP2958562A4
(en)
|
2013-02-22 |
2016-08-10 |
Merck Sharp & Dohme |
BICYCLIC ANTIDIABETIC COMPOUNDS
|
CN104059039B
(zh)
|
2013-03-22 |
2017-03-15 |
正大天晴药业集团股份有限公司 |
具有gpr40受体功能调节作用的稠环化合物
|
CN104109115B
(zh)
|
2013-04-16 |
2016-11-23 |
中国科学院上海药物研究所 |
一种含氮杂环链接的苯丙酸类化合物、其药物组合物、制备方法和用途
|
WO2014170842A2
(en)
|
2013-04-17 |
2014-10-23 |
Piramal Enterprises Limited |
Substituted alkyl carboxylic acid derivatives as gpr agonists
|
WO2014187343A1
(zh)
|
2013-05-22 |
2014-11-27 |
四川海思科制药有限公司 |
苯并呋喃衍生物、其制备方法及其在医药上的应用
|
KR20160034893A
(ko)
|
2013-06-13 |
2016-03-30 |
패스트 포워드 파머슈티컬스 비.브이. |
Cd40 시그널링 억제제 및 추가 화합물로서, 상기 추가 화합물은 담즙산, 담즙산 유도체, tgr5-수용체 아고니스트, fxr 아고니스트 또는 이들의 조합이고, 만성 염증의 치료용, 및 위장 암 또는 섬유증의 예방용인, cd40 시그널링 억제제 및 추가 화합물
|
CN104507921B
(zh)
|
2013-07-02 |
2017-02-22 |
四川海思科制药有限公司 |
苯并环丁烯类衍生物、其制备方法及其在医药上的应用
|
CN105143181B
(zh)
|
2013-07-26 |
2017-12-26 |
四川海思科制药有限公司 |
三元并环羧酸类衍生物、其制备方法及其在医药上的应用
|
EA202092386A1
(ru)
|
2013-07-31 |
2021-04-30 |
Эмджен Инк. |
Конструкции на основе фактора дифференцировки и роста 15 (gdf15)
|
PT3031799T
(pt)
|
2013-08-09 |
2018-07-04 |
Takeda Pharmaceuticals Co |
Composto aromático
|
CN104418801B
(zh)
|
2013-08-19 |
2016-10-05 |
上海润诺生物科技有限公司 |
苯并哌啶环与苯并吗啉环类化合物、其制法及医药应用
|
WO2015024526A1
(en)
|
2013-08-23 |
2015-02-26 |
Fujian Haixi Pharmaceuticals Co., Ltd |
Carboxylic acid compounds in treatment of diabetes mellitus
|
WO2015028960A1
(en)
|
2013-08-28 |
2015-03-05 |
Piramal Enterprises Limited |
Substituted heterocyclic derivatives as gpr agonists and uses thereof
|
WO2015032328A1
(zh)
|
2013-09-03 |
2015-03-12 |
四川海思科制药有限公司 |
茚满衍生物及其制备方法和在医药上的应用
|
WO2015044073A1
(en)
|
2013-09-26 |
2015-04-02 |
Boehringer Ingelheim International Gmbh |
Process and intermediates for preparing indanyloxydihydrobenzofuranyl acetic acid derivatives as gpr40 agonists
|
JO3442B1
(ar)
|
2013-10-07 |
2019-10-20 |
Takeda Pharmaceuticals Co |
مضادات ذات نوع فرعي من مستقبل سوماتوستاتين 5 (sstr5)
|
WO2015051496A1
(en)
|
2013-10-08 |
2015-04-16 |
Merck Sharp & Dohme Corp. |
Antidiabetic tricyclic compounds
|
WO2015062486A1
(en)
|
2013-10-31 |
2015-05-07 |
Sunshine Lake Pharma Co., Ltd. |
Biphenyl compounds and uses thereof
|
EA201690888A1
(ru)
|
2013-11-14 |
2016-10-31 |
Кадила Хелзкэр Лимитед |
Новые гетероциклические соединения
|
WO2015073342A1
(en)
|
2013-11-15 |
2015-05-21 |
Merck Sharp & Dohme Corp. |
Antidiabetic tricyclic compounds
|
WO2015078802A1
(en)
|
2013-11-28 |
2015-06-04 |
Boehringer Ingelheim International Gmbh |
New indanyloxyphenylcyclopropanecarboxylic acids
|
EP3076959B1
(en)
|
2013-12-04 |
2018-07-04 |
Merck Sharp & Dohme Corp. |
Antidiabetic bicyclic compounds
|
TW201609722A
(zh)
|
2013-12-13 |
2016-03-16 |
美國禮來大藥廠 |
新穎***并吡啶化合物
|
WO2015089809A1
(en)
|
2013-12-19 |
2015-06-25 |
Merck Sharp & Dohme Corp. |
Antidiabetic substituted heteroaryl compounds
|
JP6170255B2
(ja)
|
2014-01-10 |
2017-07-26 |
イーライ リリー アンド カンパニー |
イソプロピルトリアゾロピリジン化合物
|
AU2015204923A1
(en)
|
2014-01-10 |
2016-06-09 |
Eli Lilly And Company |
Phenyl-triazolo-pyridine compounds
|
US10059667B2
(en)
|
2014-02-06 |
2018-08-28 |
Merck Sharp & Dohme Corp. |
Antidiabetic compounds
|
US10077241B2
(en)
|
2014-04-15 |
2018-09-18 |
Jansen Pharmaceutica Nv |
Tetrahydro-benzoimidazolyl modulators of TGR5
|
WO2015176267A1
(en)
|
2014-05-22 |
2015-11-26 |
Merck Sharp & Dohme Corp. |
Antidiabetic tricyclic compounds
|
US10166246B2
(en)
|
2014-05-27 |
2019-01-01 |
City Of Hope |
TGR5 agonist complexes for treating diabetes and cancer
|
DK3626725T3
(da)
|
2014-05-29 |
2023-02-27 |
Bar Pharmaceuticals S R L |
Cholan-derivater til anvendelse ved behandlingen og/eller forebyggelsen af fxr- og tgr5/gpbar1-medierede sygdomme
|
US20170204149A1
(en)
|
2014-06-23 |
2017-07-20 |
Novartis Ag |
Hsa-gdf-15 fusion polypeptide and use thereof
|
EP3164538A1
(en)
|
2014-07-02 |
2017-05-10 |
Arçelik Anonim Sirketi |
Built-in household appliance unpowered control and status indication device
|
EP3177285B1
(en)
|
2014-08-08 |
2020-09-23 |
Merck Sharp & Dohme Corp. |
[5,6]-fused bicyclic antidiabetic compounds
|
US10968193B2
(en)
|
2014-08-08 |
2021-04-06 |
Merck Sharp & Dohme Corp. |
Antidiabetic bicyclic compounds
|
US10662171B2
(en)
|
2014-08-08 |
2020-05-26 |
Merck Sharp & Dohme Corp. |
Antidiabetic bicyclic compounds
|
WO2016019587A1
(en)
|
2014-08-08 |
2016-02-11 |
Merck Sharp & Dohme Corp. |
[7, 6]-fused bicyclic antidiabetic compounds
|
WO2016032120A1
(ko)
|
2014-08-27 |
2016-03-03 |
씨제이헬스케어 주식회사 |
신규한 아미노-페닐-설포닐-아세테이트 유도체 및 이의 용도
|
US20180236064A1
(en)
|
2014-10-03 |
2018-08-23 |
Mayo Foundation For Medical Education And Research |
Targeting tgr5 to treat disease
|
TW201629033A
(zh)
|
2014-10-08 |
2016-08-16 |
健生藥品公司 |
作為治療第二型糖尿病之gpr40促效劑的經取代苯并噻吩基衍生物
|
KR101726819B1
(ko)
*
|
2014-10-27 |
2017-04-13 |
동아에스티 주식회사 |
Gpr119 작용 활성을 갖는 화합물, 이의 제조방법 및 이를 유효성분으로 함유하는 약제학적 조성물
|
CA2965560A1
(en)
|
2014-10-31 |
2016-05-06 |
Gubra Aps |
Compositions and peptides having dual glp-1r and glp-2r agonist activity
|
WO2016073767A1
(en)
|
2014-11-06 |
2016-05-12 |
Enanta Pharmaceuticals, Inc. |
Bile acid analogs an fxr/tgr5 agonists and methods of use thereof
|
WO2016086115A1
(en)
|
2014-11-26 |
2016-06-02 |
Enanta Pharmaceuticals, Inc. |
Tetrazole derivatives of bile acids as fxr/tgr5 agonists and methods of use thereof
|
US10246483B2
(en)
|
2015-02-11 |
2019-04-02 |
Enanta Pharmaceuticals, Inc. |
Bile acid analogs as FXR/TGR5 agonists and methods of use thereof
|
NZ735126A
(en)
|
2015-03-31 |
2022-10-28 |
Enanta Pharm Inc |
Bile acid derivatives as fxr/tgr5 agonists and methods of use thereof
|
TW201712012A
(zh)
|
2015-06-16 |
2017-04-01 |
美國禮來大藥廠 |
2-側氧基-1,3,8-三氮雜螺[4.5]癸-3-基羧酸衍生物
|
SI3310801T1
(sl)
|
2015-06-19 |
2021-10-29 |
Intercept Pharmaceuticals Inc |
Modulatorji TGR5 in postopki za uporabo le-teh
|
JP6772133B2
(ja)
|
2015-07-02 |
2020-10-21 |
サントリーホールディングス株式会社 |
Glp−2分泌促進用組成物
|
US20170008928A1
(en)
|
2015-07-06 |
2017-01-12 |
Novo Nordisk A/S |
Novel peptides and peptide derivatives and uses thereof
|
KR20180028544A
(ko)
|
2015-08-07 |
2018-03-16 |
인터셉트 파마슈티컬즈, 인크. |
담즙산 및 이의 유도체의 제조 방법
|
JP6816107B2
(ja)
|
2015-08-07 |
2021-01-20 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
インダニルアミノピリジルシクロプロパンカルボン酸、医薬組成物及びこれらの使用
|
US9856245B2
(en)
|
2015-08-12 |
2018-01-02 |
Janssen Pharmaceutica Nv |
GPR40 agonists for the treatment of type II diabetes
|
WO2017027310A1
(en)
|
2015-08-12 |
2017-02-16 |
Janssen Pharmaceutica Nv |
Gpr40 agonists for the treatment of type ii diabetes
|
WO2017027309A1
(en)
|
2015-08-12 |
2017-02-16 |
Janssen Pharmaceutica Nv |
Gpr40 agonists for the treatment of type ii diabetes
|
WO2017042121A1
(en)
|
2015-09-09 |
2017-03-16 |
Boehringer Ingelheim International Gmbh |
[{[2,3-dihydro-1h-inden-1-yl]amino}-2h,3h-furo[3,2-b]pyridin-3-yl]acetic acids, pharmaceutical compositions and uses thereof
|
WO2017053826A1
(en)
|
2015-09-24 |
2017-03-30 |
Intercept Pharmaceuticals, Inc. |
Methods and intermediates for the preparation bile acid derivatives
|
US10604545B2
(en)
|
2015-11-06 |
2020-03-31 |
Intercept Pharmaceuticals, Inc. |
Methods for the preparation of obeticholic acid and derivatives thereof
|
TWI773657B
(zh)
|
2015-12-18 |
2022-08-11 |
美商亞德利克斯公司 |
作爲非全身tgr5促效劑之經取代之4-苯基吡啶化合物
|
US10364267B2
(en)
|
2016-02-23 |
2019-07-30 |
Enanta Pharmaceuticals, Inc. |
Deuterated bile acid derivatives as FXR/TGR5 agonists and methods of use thereof
|
WO2017147174A1
(en)
|
2016-02-23 |
2017-08-31 |
Enanta Pharmaceuticals, Inc. |
Heteroaryl containing bile acid analogs as fxr/tgr5 agonists and methods of use thereof
|
WO2017147137A1
(en)
|
2016-02-23 |
2017-08-31 |
Enanta Pharmaceuticals, Inc. |
Benzoic acid derivatives of bile acid as fxr/tgr5 agonists and methods of use thereof
|
JP2019510739A
(ja)
|
2016-02-29 |
2019-04-18 |
イーライ リリー アンド カンパニー |
Gfral受容体療法
|
US10676458B2
(en)
|
2016-03-29 |
2020-06-09 |
Merch Sharp & Dohne Corp. Rahway |
Antidiabetic bicyclic compounds
|
WO2017180571A1
(en)
|
2016-04-11 |
2017-10-19 |
Janssen Pharmaceutica Nv |
Substituted benzothiophenyl derivatives as gpr40 agonists for the treatment of type ii diabetes
|
CA3020698A1
(en)
|
2016-04-13 |
2017-10-19 |
Intercept Pharmaceuticals, Inc. |
Methods of treating or preventing hepatocellular carcinoma
|
WO2018005801A2
(en)
|
2016-07-01 |
2018-01-04 |
Venenum Biodesign Llc |
Novel non-systemic tgr5 agonists
|
WO2018005794A2
(en)
|
2016-07-01 |
2018-01-04 |
Venenum Biodesign Llc |
Novel non-systemic tgr5 agonists
|
WO2018009778A1
(en)
|
2016-07-07 |
2018-01-11 |
Baylor College Of Medicine |
Combination of glp-1 and glp-2 for treating or preventing metabolic diseases, disorders and syndromes
|
CN109963567A
(zh)
|
2016-09-30 |
2019-07-02 |
英特塞普特医药品公司 |
胆汁酸衍生物的结晶形式
|
WO2018071493A1
(en)
|
2016-10-12 |
2018-04-19 |
Janssen Biotech, Inc. |
Methods for screening for modulators of gdf15-like biological activity
|
US10988433B2
(en)
|
2016-10-25 |
2021-04-27 |
Janssen Pharmaceutica Nv |
Cyclohexyl GPR40 agonists for the treatment of type II diabetes
|
WO2018077699A1
(en)
|
2016-10-25 |
2018-05-03 |
Boehringer Ingelheim International Gmbh |
Benzylaminopyridylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof
|
JP7008704B2
(ja)
|
2016-11-28 |
2022-01-25 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
インダニルアミノピリジルシクロプロパンカルボン酸、その医薬組成物及び使用
|
EP3551176A4
(en)
|
2016-12-06 |
2020-06-24 |
Merck Sharp & Dohme Corp. |
ANTIDIABETIC HETEROCYCLIC COMPOUNDS
|
WO2018103868A1
(en)
|
2016-12-09 |
2018-06-14 |
Zealand Pharma A/S |
Acylated glp-1/glp-2 dual agonists
|
SG11201903938XA
(en)
|
2016-12-09 |
2019-05-30 |
Zealand Pharma As |
Acylated glp-1/glp-2 dual agonists
|
WO2018104558A1
(en)
|
2016-12-09 |
2018-06-14 |
Zealand Pharma A/S |
Acylated glp-1/glp-2 dual agonists
|
US11130793B2
(en)
|
2016-12-09 |
2021-09-28 |
Zealand Pharma A/S |
GLP-1/GLP-2 dual agonists
|
WO2018104559A1
(en)
|
2016-12-09 |
2018-06-14 |
Zealand Pharma A/S |
Glp-1/glp-2 dual agonists
|
KR102007633B1
(ko)
|
2016-12-15 |
2019-08-06 |
일동제약(주) |
신규 페닐 프로피온 산 유도체 및 이의 용도
|
WO2018118670A1
(en)
|
2016-12-20 |
2018-06-28 |
Merck Sharp & Dohme Corp. |
Antidiabetic spirochroman compounds
|
WO2018138028A1
(en)
|
2017-01-26 |
2018-08-02 |
Boehringer Ingelheim International Gmbh |
Benzylaminopyrazinylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof
|
JP7023969B2
(ja)
|
2017-01-26 |
2022-02-22 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
ベンジルアミノピリジルシクロプロパンカルボン酸、その医薬組成物及び使用
|
WO2018138029A1
(en)
|
2017-01-26 |
2018-08-02 |
Boehringer Ingelheim International Gmbh |
Benzyloxypyridylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof
|
EP3573969A1
(en)
|
2017-01-26 |
2019-12-04 |
Boehringer Ingelheim International GmbH |
Benzyloxypyrazinylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof
|
CN110214135B
(zh)
|
2017-01-26 |
2023-02-21 |
勃林格殷格翰国际有限公司 |
茚满基氨基吡嗪基环丙烷羧酸、药物组合物及其用途
|
WO2018142363A1
(en)
|
2017-02-06 |
2018-08-09 |
Orbicular Pharmaceutical Technologies Private Limited |
Ready to use compositions of glp-2 analogues through self-administrable devices
|
EP3580222B1
(en)
|
2017-02-08 |
2021-04-07 |
Boehringer Ingelheim International GmbH |
Indanylaminoazadihydrobenzofuranylacetic acids, pharmaceutical compositions for the treatment of diabetes
|
GB201704714D0
(en)
|
2017-03-24 |
2017-05-10 |
Caldan Therapeutics Ltd |
Pharmaceutical compounds
|
AR111199A1
(es)
|
2017-03-31 |
2019-06-12 |
Takeda Pharmaceuticals Co |
Compuesto aromático agonista de gpr40
|
WO2018181847A1
(ja)
|
2017-03-31 |
2018-10-04 |
武田薬品工業株式会社 |
芳香環化合物
|
CN107162921B
(zh)
|
2017-05-27 |
2019-12-13 |
中国药科大学 |
一类苯氧乙酸衍生物、其制备方法及其作为药物的用途
|
WO2018222701A1
(en)
|
2017-05-30 |
2018-12-06 |
Intercept Pharmaceuticals, Inc. |
Treatment of renal diseases with a bile acid derivative
|
WO2018226724A1
(en)
|
2017-06-05 |
2018-12-13 |
Intercept Pharmaceuticals, Inc. |
Treatment and prevention of diabetic eye diseases with a bile acid derivatives
|
TWI791539B
(zh)
|
2017-06-16 |
2023-02-11 |
丹麥商西蘭製藥公司 |
用於投予類升糖素胜肽-2(glp-2)類似物的給藥方案
|
BR112019027458A2
(pt)
|
2017-06-23 |
2020-07-07 |
Intercept Pharmaceuticals, Inc. |
métodos e intermediários para a preparação de derivados de ácidos biliares
|
BR112020003736A2
(pt)
|
2017-08-22 |
2020-09-08 |
Shire-Nps Pharmaceuticals, Inc. |
polipeptídeos de fusão de glp-2 e usos para tratar e prevenir condições gastrointestinais
|
WO2019086559A1
(fr)
|
2017-10-31 |
2019-05-09 |
Adocia |
Composition comprenant un agoniste du recepteur du glp-2 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes
|
EP3706774A4
(en)
|
2017-11-06 |
2021-09-08 |
Shire-NPS Pharmaceuticals, Inc. |
GLP-2 ANALOGUES AND PEPTIBODIES FOR USE BEFORE, DURING OR AFTER SURGICAL PROCEDURE
|
WO2019099315A1
(en)
|
2017-11-16 |
2019-05-23 |
Merck Sharp & Dohme Corp. |
Antidiabetic bicyclic compounds
|
US11964938B2
(en)
|
2018-01-08 |
2024-04-23 |
Celon Pharma S.A. |
3-phenyl-4-hexynoic acid derivatives as GPR40 agonists
|
WO2020197926A1
(en)
|
2019-03-22 |
2020-10-01 |
Kallyope, Inc. |
Gpcr combination therapies
|
EP3976576A4
(en)
|
2019-05-29 |
2023-06-28 |
Kallyope, Inc. |
Gpr40 agonists
|
EP4041722A4
(en)
*
|
2019-10-07 |
2023-12-13 |
Kallyope, Inc. |
GPR119 AGONISTS
|
AU2020398874A1
(en)
|
2019-12-03 |
2022-06-23 |
Kallyope, Inc. |
SSTR5 antagonists
|
CA3173731A1
(en)
|
2020-02-28 |
2021-09-02 |
Kallyope, Inc. |
Gpr40 agonists
|
EP4110760A1
(en)
|
2020-02-28 |
2023-01-04 |
Kallyope, Inc. |
Gpr40 agonists
|